HELP
Helus Pharma Inc. Common Stock
Nasdaq · usd
Helus Pharma Inc. Common Stock (HELP) trades at $10.61 (+4.12%) as of 2:23:43 PM EDT on Oct 26, 2026, -15.44% over the past month. Market cap is $744.58M, with 1.7 days to cover in short interest.
Stock performance
How Helus Pharma Inc. Common Stock (HELP) stock has performed from one day to one year, with its 52-week range.
- 1D
- +4.64%
- 1W
- -0.26%
- 1M
- -15.44%
- YTD
- +37.94%
- 1Y
- +37.94%
- 52-wk range
- $3.76 – $15.15
Key statistics
Today's trading snapshot for HELP: day range, open, previous close, volume and market cap.
- Day range
- $10.06 – $10.90
- Open
- $10.08
- Prev close
- $10.19
- Volume
- 770.03K
- Market cap
- $744.58M
- Shares out
- 79.81M
HELP short interest
How heavily HELP is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 1.7
- Short interest
- 3.46M
- Avg volume
- 1.99M
As of · reported to FINRA twice monthly.
Frequently asked questions
What is the Helus Pharma Inc. Common Stock (HELP) stock price today?
Helus Pharma Inc. Common Stock (HELP) is trading at $10.61 (+4.12% on the day) as of 2:23:43 PM EDT on Oct 26, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Helus Pharma Inc. Common Stock?
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways.
What is the short interest in HELP?
As of Sep 30, 2026, HELP has 3.46M shares short and 1.7 days to cover.
What exchange is HELP listed on?
Helus Pharma Inc. Common Stock (HELP) trades on Nasdaq in USD.
Build with AI
Build an analysis of HELP with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a HELP analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.